TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low Energy Therapy to Convert Ventricular Tachycardias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a history of ventricular tachycardia indicated for ventricular testing procedures that may include VT induction, such as VT testing, VT ablation, VT mapping, or VT risk stratification testing.~* Subjects age 18 or above, or of legal age to give written informed consent specific to local laws and requirements~* Subjects who, in the opinion of the investigator, are suitable to be enrolled in a clinical study~Exclusion Criteria:~* Subjects with any comorbidities that, in the opinion of the investigator, would exclude them from standard of care VT testing~* Subjects with VT that is known to be focal in nature~* Subjects whom the investigator believes are not hemodynamically stable enough to tolerate testing~* Subjects of childbearing age who may be pregnant.~* Subjects who are unwilling or unable to provide written informed consent.~* Subjects with any implanted device that emits electrical energy where either therapy cannot be temporarily disabled, or the subject cannot tolerate temporary disabling of therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute Testing (Type: EXPERIMENTAL): Single-arm study - all subjects who meet the I\&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient having signed the consent form to take part in the study~* Patient aged over 18 years, with no upper age limit~* Patient with histologically proven cholangiocarcinoma~* Patient with cholangiocarcinoma, inoperable or non resectable owing to extension, age or concomitant diseases~* Bilirubin level decrease of more than 50% after stent insertion compared to base level~* Patient with a WHO Performance Scale ≤ 2~* Patient in whom efficient drainage is performed by means of a plastic biliary stent endoscopically or radiologically~* Patient capable of completing the quality of life questionnaires~* Women of child-bearing potential must have a negative pregnancy test, and must thereafter prove to be using acceptable contraception (oral contraceptive pill, hormone patches, or IUD)~Exclusion Criteria:~* Absence of consent to take part in the study~* Patient with operable biliary carcinoma~* Class ASA IV patients~* Patients presenting clinical and laboratory signs of biliary infection~* Absence of bilirubin decrease after stent insertion~* Patients with extrinsic biliary compression~* Patients already having received or currently receiving radiotherapy or chemotherapy for cholangiocarcinoma or needing to be treated during the first month of the follow-up~* Known metastatic lesions~* Patients having received immediate treatment by insertion of a metal stent~* Patients with porphyria or known hypersensitivity to porphyrins (contraindication to WST11)~* Patient receiving prohibited treatment at the time of inclusion in the study~* Pregnant or breast-feeding women~* Non-menopausal women not using effective contraception~* Majors under protection as per the French Public Health Code~* Persons not registered with or covered by a social security system~* Persons in an exclusion period relative to other biomedical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WST11 (Type: EXPERIMENTAL): Treatment with WST11-mediated VTP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Antibiotics Prior to Embryo Transfer (PAPET): RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The female partner must be aged 18-43 years and going through a fresh IVF cycle~Exclusion Criteria:~* Couples will be excluded from enrollment if they have any contraindication to antibiotic treatment, are not intending to undergo embryo transfer (fertility preservation patients and oocyte donors), require use of extended antibiotic coverage at time of egg retrieval, are already on antibiotics for any reason (e.g., upper respiratory infection), have a recent history of pelvic infection, or are planning on limited insemination (inseminating a limited number of the eggs retrieved) or are using donor sperm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- Prophylactic antibiotics (Type: NO_INTERVENTION): Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
- No antibiotic prophylaxis. (Type: EXPERIMENTAL): Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~- Adult patients with histologically or cytologically confirmed cholangiocarcinoma at the time of diagnosis.~Patients with cancers of the gallbladder or ampulla of Vater are not eligible.~- Patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/ metastatic disease. Patient should have evidence of progressive disease following prior regimen, or if prior treatment discontinued due to toxicity must have continued evidence of measurable or evaluable disease.~Exclusion criteria:~* Prior or current treatment with a MEK inhibitor (all Cohorts), BGJ398 (infigratinib) (all Cohorts), or selective FGFR inhibitor (Cohorts 1 and 2 only).~* insufficient organ function~  * Absolute Neutrophil Count (ANC) \< 1,000/mm3 \[1.0 x 10\^9/L\]~ * Platelets \< 75,000/mm3 \[75 x 10\^9/L\]~ * Hemoglobin \< 109.0 g/dL~ * Total bilirubin \> 1.5x upper limit of normal (ULN)~ * Aspartate aminotransferase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/glutamic pyruvic transaminase (ALT/SGPT) \> 2.5x ULN (AST and ALT \> 5x ULN in the presence of liver metastases)~ * Serum creatinine \> 1.5x ULN and a calculated or measured creatinine clearance \< 45 mL/min~ * Inorganic phosphorus outside of normal limits~ * Total and ionized serum calcium outside of normal limits~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BGJ398 (infigratinib) (Type: EXPERIMENTAL): To estimate the anti-tumor activity of BGJ398 (infigratinib)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes~* Patients treated by metformin and/or sulfonylureas (or glinides) and/or acarbose and/or insulin,~* HbA1C \>= 7 %,~* Patients who gave their written consent.~For the kinetic substudy:~* Patients who have the typical features of diabetic dyslipidemia (triglycerides \>= 1.50 g/l and/or HDL\<0.50 g/l \[women\], 0.40 g/l \[men\])~Exclusion Criteria:~* Treatment with thiazolidinediones or other Glucagon-like peptide-1(GLP1) agonist.~* No treatment with a Dipeptidyl peptidase-4 (DPP4) inhibitor during the 3 previous months,~* Renal or hepatic failure,~* Contra-indication for proton-spectroscopy (pacemaker, implantable prosthesis,..),~* Pregnancy.~For the kinetic substudy:~* Patients on hypolipidemic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Main study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with end-stage liver disease who are listed for liver transplant~* Have failed the non-invasive approach to weight loss to be actively listed for transplant (requiring 2 clinical return visits without weight loss of \>5 kg)~* Body Mass Index (BMI) \>35~* Negative pregnancy test for females who are able to get pregnant and are of child-bearing age~Exclusion Criteria:~* A previous history of gastric or bariatric surgery~* Current or recent (within 6 months) gastric or duodenal ulcers~* Moderate to severe Portal hypertension defined as portal gastropathy graded as \>= to moderate/severe, gastric varices, or esophageal varices graded \> = moderate/large (Patients with varices which have been obliterated may be included).~* Calculated Model of End-stage Liver Disease (MELD) score \>25 or childs score \>10~* The presence of more than one gastric balloon at the same time~* Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease.~* A large hiatal hernia or \>5 cm hernia or ≤5 cm with associated severe or intractable gastro-esophageal reflux symptoms.~* A structural abnormality in the esophagus or pharynx such as a stricture or diverticulum that could impede passage of the delivery catheter and/or an endoscope.~* Achalasia or any other severe motility disorder that may pose a safety risk during removal of the device.~* Gastric mass~* Severe coagulopathy~* Patients who are known to have or suspected to have an allergic reaction to materials contained in ORBERA.~* Serious or uncontrolled psychiatric illness or disorder that could compromise patient understanding of or compliance with follow up visits and removal of the device after 6 months.~* Alcoholism or drug addiction~* Patients who are unable or unwilling to take prescribed proton pump inhibitor medication for the duration of the device implant~* Patients unwilling to participate in an established medically-supervised diet and behavior modification program, with routine medical follow-up.~* Patients receiving aspirin, anti-inflammatory agents, anticoagulants or other gastric irritants, not under medical supervision.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orbera Intragastric Balloon (Type: EXPERIMENTAL): All subjects will be receiving the ORBERA Intragastric Balloon

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age of at least 18 years at study entry;~2. Histologically confirmed adenocarcinoma of the prostate;~3. 68Ga-PSMA-PET exam performed between October 2015 and January 2021;~4. 68Ga-PSMA-PET performed in one of the following situations:~   * localized disease at diagnosis in patients with no detection of extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan;~  * biochemical recurrence (according to PCWG3 or defined by the investigator) in patients with no detection of prostatic or extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan;~5. Traditional imaging (pelvic and abdominal CT or MRI and bone scan) with negative results (no extra-prostatic disease, for localized and biochemical recurrence disease; no prostatic for biochemical recurrence disease) performed within 8 weeks before 68Ga-PSMA-PET;~6. Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records.~Exclusion Criteria:~1. Patients with no disease characteristics accessible in medical records;~2. Cancer diagnosis other than prostate cancer in the last 5 years;~3. Disease detected by traditional imaging techniques (bone scan, CT and/or MRI), meaning extra-prostatic disease, for localized and biochemical recurrence disease; or prostatic disease for biochemical recurrence disease.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed type 1 diabetes within 1 week of diagnosis~* Age 6 - 18 years~* Care provided at Children's Medical Center, Dallas~Exclusion Criteria:~* Actual treatment with oral drugs influencing beta cell function or blood glucose levels (e.g. oral hypoglycemic agents)~* Actual treatment with drugs influencing insulin sensitivity (e.g. Metformin, or systemic steroids)~* Significant concomitant disease likely to interfere with glucose metabolism (children with active bacterial infections at the time of diagnosis must be cured prior to entry)~* Expected poor compliance~* Pregnancy~* Any other condition that by the judgement of the investigator may be potentially harmful to the patients

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Detemir (Type: EXPERIMENTAL): 24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
- Glargine (Type: EXPERIMENTAL): 24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
- NPH (Type: EXPERIMENTAL): 24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Mixed Incontinence: Medical Or Surgical Approach?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female~2. Mixed UI as evidenced by stress and urge symptoms reported on MESA (either percent of urge-type symptoms ≥ the percent of stress-type symptoms or urge symptom score ≥7 if stress predominant) followed by report of moderately or greatly/quite a bit bothered to questions 2 and 3 of the 6-item Urinary Distress Index (UDI-6) or questions 16 and 17 of the 20-item Pelvic Fl;oor Distress Index (PFDI-20), respectively (See Appendix C)~3. Moderate or severe UI as evidenced by the corresponding response on the Patient Global Impression of Severity (PGI-S)~4. Incontinence symptoms present for at least (3) months\*~5. Bladder capacity \> 200cc (by any method)~6. Urodynamic Stress Incontinence~7. Eligible for both treatment interventions~8. Available to start intervention within 6 weeks~9. Negative urine dipstick (negative result = trace or less for leukocytes \& nitrites)~10. Available for 12 months of follow-up and able to complete study assessments as per clinician judgment~11. Signed consent form~Exclusion Criteria:~1. Age \<21 years\*~2. Currently undergoing or recommended to undergo treatment of pelvic organ prolapse~3. Other indicated/planned concomitant surgery~4. Pregnant or has not completed child bearing\*~5. \<12 months post-partum\*†~6. Active malignancy of cervix, uterus, fallopian tube(s) or ovary \> Stage I, or bladder of any Stage~7. Current catheter use~8. Unevaluated hematuria~9. Participation in another trial that may influence the results of this study~   * Patient can be rescreened after respective time interval has been met. †Partum is defined as a delivery or other termination that occurs after 20 weeks gestation.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Surgical Treatment (Type: ACTIVE_COMPARATOR): Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
- Non Surgical Treatment (Type: ACTIVE_COMPARATOR): The non-surgical treatment will include two components:~1. Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~2. Behavioral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Duration in Post-appendectomy Abscess

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 2 to 17 years of age~* Diagnosis of perforated appendicitis at laparoscopy~* Development of a post-appendectomy abscess that is treated with percutaneous drainage.~Exclusion Criteria:~* Patients who are allergic to ampicillin

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 8-day (Type: OTHER): 8-day course of ampicillin clavulanate antibiotic
- 4-day (Type: OTHER): 4--day course of ampicillin clavulanate antibiotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute myeloid leukemia according to the WHO classification~* Informed consent in place for a randomized study of the Study Alliance Leukemia (SAL) including the Heidelberg Leukemia Network (HeLeNe) covering assessment of MRD by MPFC in the reference laboratories in Heidelberg and Dresden.~Exclusion Criteria:~* No signed informed consent compliant with the requirements of PERDAM

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Optimized Supervised Education Program for Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 to 75 years~* With peripheral arterial disease~* Who accept to follow a patient education program~Exclusion Criteria:~* Permanent limb ischemia~* Revascularisation programmed in the 6 next months~* Other severe prognostic disease~* Difficulties to obtain patient consent because of language or understanding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- patient education (Type: EXPERIMENTAL): individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
- Usual care (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues